Citations

Clear

3942 citation(s) found for "To, Van".

Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma
Dewald, Gordon W., Therneau, Terry M. , Lee, You Kyoung , Fink, Stephanie, Smoley, Stephanie A., Paternoster, Sarah F., Adeyinka, Adewale, Ketterling, Rhett P. , Dyke, Daniel L. Van , Fonseca, Rafaël , Kyle, Robert A. , Larson, Dirk R. , Ketterling, Rhett P , Fonseca, Rafael

Mayo Clinic

Blood | July 20, 2005 | Volume: 106 | Issue: 10 | Pages: 3553-3558

10.1182/blood-2005-05-1981 | PMID 16030187 Get It

AbstractThe clinical efficacy of evaluating genetic anomalies in metaphase cells versus interphase nuclei for multiple myeloma (MM) is poorly understood. Therefore, survival for 154 patients with newly diagnosed untreated MM was compared with results from analysis of metaphase and interphase cells. Metaphases were studied by conventional cytogenetics and fluorescent-labeled DNA probes (fluorescence in situ hybridization [FISH]), whereas inter-phase nuclei were evaluated only by FISH. All FISH studies were done using DNA probes to detect t(4;14)(p16;q32), t(11;14)(q13;q32), t(14;16)(q32;q23), del(17) (p13.1), and chromosome 13 anomalies. Metaphases were abnormal by cytogenetics and/or metaphase FISH in 61 (40%) patients. Abnormal interphase nuclei were observed in 133 (86%) patients, including each patient with abnormal metaphases. FISH was a necessary adjunct to cytogenetics to detect t(4;14) and t(14;16) in metaphase cells. Patient survival was especially poor for patients with greater than 50% abnormal interphase nuclei, although this result was more likely due to level of plasma cells than specific chromosome anomalies. For metaphase data, patients with t(4;14), t(14;16), del(17) (p13.1), and/or chromosome 13 anomalies (primarily monosomy 13) had poor survival. A different outcome was observed for interphase data as patients with t(4;14) or t(14;16) had poor survival, whereas patients with chromosome 13 anomalies had intermediate survival: interphase FISH did not substitute for metaphase analysis.
Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies
LoRusso, Patricia , Adjei, Alex A. , Varterasian, Mary , Mitchell, David, Hanson, Lorelei J., DeLuca, Pamela, Bruzek, Laura M., Piens, Jill, Asbury, Peggy, Becelaere, Keri Van, Herrera, Román, Gadgeel, Shirish M. , Reid, Joel M. , Sebolt–Leopold, Judith S. , Meyer, Mark B.

Mayo Clinic

Journal of Clinical Oncology | July 12, 2005 | Volume: 23 | Issue: 23 | Pages: 5281-5293

10.1200/jco.2005.14.415 | PMID 16009947 Get It

Purpose This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD), and clinical activity of CI-1040, a small-molecule inhibitor of the dual-specificity kinases MEK(mitogen-activated protein kinase kinase) -1 and MEK2 , in patients with advanced malignancy. Patients and Methods CI-1040 was tested in multiple daily dosing frequencies administered for 21 days repeated every 28 days leading ultimately to continuous administration, and effect of food on absorption was tested. Single dose and steady-state pharmacokinetics were assessed during cycle 1 and phosphorylated extracellular receptor kinase (pERK) levels were assessed in WBCs and also in tumor tissue from selected patients. Results Seventy-seven patients received CI-1040 at dose levels ranging from 100 mg QD to 800 mg tid. Grade 3 asthenia was dose limiting at the highest dose level tested, 800 mg tid administered with food. Ninety-eight percent of all drug-related adverse events were grade 1 or 2 in severity; most common toxicities included diarrhea, asthenia, rash, nausea, and vomiting. Plasma concentrations of CI-1040 and its active metabolite, PD 0184264, increased in a less than dose proportional manner from 100 to 800 mg QD. Administration with a high-fat meal resulted in an increase in drug exposure. The MTD and recommended phase II dose was 800 mg BID administered with food. Sixty-six patients were assessable for response. One partial response was achieved in a patient with pancreatic cancer and 19 patients (28%) achieved stable disease lasting a median of 5.5 months (range, 4 to 17 months). Inhibition of tumor pERK (median, 73%; range, 46% to 100%) was demonstrated in 10 patients. Conclusion CI-1040 was well tolerated at 800 mg BID administered with food. Both target suppression and antitumor activity were demonstrated in this phase I study.
The diagnostic challenge of postoperative acute appendicitis
Barr, Darlene, Heerden, Jon A. van, Mucha, Peter

Mayo Clinic

World Journal of Surgery | May 11, 2005 | Volume: 15 | Issue: 4 | Pages: 526-528

10.1007/bf01675654 | PMID 1891940 Get It

AbstractDuring the period 1979 to 1989, 0.1 % of all cases of acute appendicitis at our institution occurred soon after another operative procedure. The interval between primary operation and appendectomy was 5 to 31 days (mean, 14 days). Signs and symptoms did not differ from those of classical acute appendicitis. Duration of symptoms ranged from 12 hours to 8 days (mean, 2.4 days). Perforation was present in 3 patients, suppurative appendicitis in 1 patient, and acute inflammation in 4 patients. Two of the perforations were associated with abscess formation. Morbidity related to the appendiceal condition included hepatic abscesses, septic shock, and prolonged ileus. There was no mortality. Hospitalization ranged from 6 to 80 days (mean, 12.5 days).
Invited commentary
Heerden, Jon A. van

Mayo Clinic

World Journal of Surgery | May 11, 2005 | Volume: 15 | Issue: 4 | Pages: 515-515

10.1007/bf01675649 Get It

Surgical treatment of primary hyperparathyroidism: An institutional perspective
Heerden, Jon A. van, Grant, Clive S.

Mayo Clinic

World Journal of Surgery | May 9, 2005 | Volume: 15 | Issue: 6 | Pages: 688-692

10.1007/bf01665301 | PMID 1767534 Get It

AbstractThree hundred and eighty‐four consecutive patients with primary hyperparathyroidism (HPT) were surgically treated at a single institution during the 2 year period 1983 through 1984. Two patients were found to have benign familial hypocalciuric hypercalcemia and a single patient had parathyroid carcinoma. In the remaining 379 patients, the cure rate was 99.5%, the operative mortality 0.3%, persistent vocal cord paralysis 0.8%, and permanent hypocalcemia 0.3%. This data supports a liberal policy regarding cervical exploration in patients with HPT and questions any policy of observation without surgical intervention.
Expression of a potential metastasis suppressor gene (nm23) in thyroid neoplasms
Farley, David R. , Eberhardt, Norman L., Grant, Clive S., Schaid, Daniel J. , Heerden, Jonathan A. van, Khosla, Sundeep , Hay, Ian , Khosla, Sundeep

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 17 | Issue: 5 | Pages: 615-620

10.1007/bf01659123 | PMID 8273382 Get It

AbstractIdentification of multiple clinical and pathologic prognostic factors in differentiated thyroid cancer has permitted some degree of risk stratification. However, these clinical indices fail to distinguish potential intrinsic differences in tumor virulence. The nm23 gene has been identified as a potential metastasis suppressor gene that is homologous to nucleoside diphosphate kinases. Studies in human breast cancer have shown a significant inverse correlation between nm23 levels and nodal involvement/tumor recurrence. Given the possible clinical utility of a marker of metastatic potential in the management of thyroid carcinoma, we examined 34 thyroid neoplasms and a human medullary thyroid cancer (MTC) cell line (TT) for nm23 expression. Normalized nm23 expression was assessed by Northern analysis of tumor RNA. nm23 Expression (tumor expression/TT cell expression, mean ±SE) was 1.14 ±0.15* in MTCs (n =5), 0.70 ±0.10* in follicular cancers (n=6), 0.51 ±0.11 in papillary cancers (n=19), and 0.31 ±0.03 in follicular adenomas (n=4) (*p< 0.05 when compared to adenomas). Within histologicgroups, we found no correlation between nm23 expression and nodal involvement or distant métastases. Our results indicate that thyroid neoplasms of different histologies express varying levels of the nm23 transcript. Although nm23 expression seems diminished in metastatic breast cancer, it appears not to be the case in metastatic thyroid cancer. The nm23 gene may therefore have different roles in the evolution and metastases of different neoplasms.
Invited commentary
Donohue, John H., Heerden, J A van

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 15 | Issue: 1 | Pages: 127-127

10.1007/bf01658983 Get It

Book review
Heerden, Jonathan A. van

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 15 | Issue: 3 | Pages: 411-411

10.1007/bf01658744 Get It

Long‐term evaluation following resection of apparently benign pheochromocytoma(s)/paraganglioma(s)
Heerden, Jonathan A. van, Roland, Christopher F., Carney, J. Aidan, Sheps, Sheldon G., Grant, Clive S.

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 14 | Issue: 3 | Pages: 325-329

10.1007/bf01658516 | PMID 1973322 Get It

AbstractIn the absence of distant disease, the pathologic diagnosis of malignancy in pheochromocytoma or paraganglioma is impossible. In an effort to establish the true incidence of recurrence in this disease, we have analyzed long‐term follow‐up (average, 15.8 years) of 98 patients who underwent complete resection of localized, noninvasive, histologically‐benign pheochromocytomas and paragangliomas at our institution between 1960 and 1976.Eighty‐eight patients had nonfamilial, sporadic pheochromoctyoma/ paraganglioma. Nine had multiple endocrine neoplasia (MEN) type 2 (2A: 7, 2B: 2), and 1 had familial pheochromocytoma. Seventy‐nine patients had single pheochromocytomas; 10 had single extraadrenal tumors (paragangliomas); and 9 had multicentric or bilateral adrenal tumors.Six patients (6.5%) developed recurrent pheochromocytoma after documentation of normal postoperative urinary catecholamine levels. One of these patients had MEN 2A. The recurrences developed at intervals from 5 to 13 years following initial resection. These were distant in 3 patients, local in 2, and both local and distant in a single patient. None of the recurrences occurred in the 13 patients who, on pathologic rereview, had either local or vascular invasion. No paraganglioma recurred.Life‐long follow‐up of all patients who have had pheochromocytomas or paragangliomas resected is mandatory.
Invited commentary
Heerden, Jonathan A. van

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 10 | Issue: 5 | Pages: 859-859

10.1007/bf01655259 Get It